Palvella Therapeutics (NASDAQ:PVLA) Issues Quarterly Earnings Results

Palvella Therapeutics (NASDAQ:PVLA) posted its quarterly earnings results on Thursday. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30), FiscalAI reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• Phase III SELVA for QTORIN rapamycin met the primary and all key secondary endpoints with a tolerable safety profile, and Palvella says an NDA submission remains on track for H2 2026 with an in-person pre-NDA meeting this quarter toward a potential H1 2027 approval.
• The company completed an upsized $230 million financing and ended Q1 with $261.9 million in cash, which management says provides runway into a potential commercial launch and through cash-flow break-even under current assumptions.
• Palvella is scaling commercial readiness—hiring experienced rare-disease launch leaders, expanding MSL coverage, and targeting a 30–40 rep field force pre-PDUFA—while estimating peak U.S. MLM sales >$1 billion and potential orphan pricing of $100k–$200k per patient per year.
• Pipeline momentum extends beyond MLM: phase III planning for cutaneous venous malformations is on track for H2 2026, the phase II LOTU angiokeratoma study has dosed its first patients ahead of schedule, and a DSAP phase II is targeted for H2 2026 amid strong patient interest.
• Management highlights the QTORIN platform as a differentiator—demonstrating dermal delivery of high?molecular?weight rapamycin, supported by multiple issued patents and formulation/manufacturing know?how aimed at creating durable exclusivity and barriers to competition.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock traded up $8.03 during trading hours on Friday, reaching $121.29. The company’s stock had a trading volume of 231,535 shares, compared to its average volume of 212,329. The stock’s fifty day simple moving average is $126.26 and its two-hundred day simple moving average is $102.43. The company has a market capitalization of $1.74 billion, a P/E ratio of -29.09 and a beta of -0.13. Palvella Therapeutics has a one year low of $20.20 and a one year high of $151.18.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elaine J. Heron acquired 2,400 shares of the stock in a transaction dated Friday, February 27th. The stock was bought at an average cost of $125.00 per share, with a total value of $300,000.00. Following the completion of the purchase, the director owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. The trade was a 5.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Palvella Therapeutics

Several institutional investors have recently made changes to their positions in the company. Group One Trading LLC grew its position in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Palvella Therapeutics by 11.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after purchasing an additional 433 shares during the period. Bank of America Corp DE boosted its holdings in shares of Palvella Therapeutics by 12.3% in the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after buying an additional 515 shares during the last quarter. Deutsche Bank AG raised its position in Palvella Therapeutics by 8.7% in the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after acquiring an additional 528 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics in the third quarter valued at about $36,000. Institutional investors own 40.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on PVLA shares. HC Wainwright boosted their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Mizuho raised their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. BTIG Research lifted their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Chardan Capital upped their price objective on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Finally, Stifel Nicolaus set a $250.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $198.07.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.